Cargando…
A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors
Autores principales: | Burris, Howard, Ansell, Stephen, Neumanitis, John, Weiss, Geoffrey, Sikic, Branimir, Northfelt, Donald, Pilja, Lana, Davis, Thomas, Yellin, Michael, Keler, Tibor, Bullock, Timothy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991281/ http://dx.doi.org/10.1186/2051-1426-1-S1-P127 |
Ejemplares similares
-
A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors
por: Ansell, Stephen, et al.
Publicado: (2013) -
Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity
por: Thomas, Lawrence J, et al.
Publicado: (2014) -
Immune correlates of Varlilumab treated cancer patients are consistent with CD27 costimulatory activity
por: Bullock, Timothy, et al.
Publicado: (2014) -
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors
por: Sanborn, Rachel E, et al.
Publicado: (2022) -
Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy
por: Vitale, Laura A., et al.
Publicado: (2020)